Cite
HARVARD Citation
Kang, M. et al. (2016). Initial Testing (Stage 1) of MK‐8242—A Novel MDM2 Inhibitor—by the Pediatric Preclinical Testing Program. Pediatric blood & cancer. 63 (10), pp. 1744-1752. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Kang, M. et al. (2016). Initial Testing (Stage 1) of MK‐8242—A Novel MDM2 Inhibitor—by the Pediatric Preclinical Testing Program. Pediatric blood & cancer. 63 (10), pp. 1744-1752. [Online].